Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haiming Chen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:

  • Bin Tang

    The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China

    7 shared publications
  • Chuanjian Lu

    State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China

    7 shared publications
  • Yujie Yang

    The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, China

    7 shared publications
  • Xuwei Zheng

    Guangzhou University of Chinese Medicine Shenzhen Hospital (Futian), Shenzhen, China

    6 shared publications
  • Qianqian Luo

    The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China

    5 shared publications
  • Yang Bi

    The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China

    5 shared publications

Latest Publications

  • Open Access

    Targeting dendritic cells with natural medicines: A novel therapeutic strategy for psoriasis

    byĀ Haixin Zhong, Xiangliang Deng, Kexin Yang, Bin Tang, Yujie Yang, Ziqing Li, Yijing Liao, Huimei Wu, Qifan Zheng, Yanfang Xian, et al.

    Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by erythematous plaques covered with silvery scales and often accompanied by pruritus, burning sensations, and pain. It is a systemic inflammatory disorder associated with increased production of pro-inflammatory cytokines by immune cells. Dendritic cells (DCs), the most potent antigen-presenting cells in the immune system, play an important role in the pathogenesis of psoriasis. The limited efficacy of current therapeutic agents may be attributable, at least in part, to an incomplete understanding of pathogenesis or suboptimal therapeutic target selection. Therefore, investigations into DCs not only provide critical insights into the pathogenesis of psoriasis but also identify a promising therapeutic target for disease management. This article describes the phenotype and function of DCs and highlights several natural medicines that regulate the onset and progression of psoriasis by regulating DC maturation and proliferation. DCs, which play a pivotal role in immune regulation, are critically involved in the pathogenesis and progression of psoriasis. Natural medicines offer diverse and effective therapeutic options for patients with psoriasis, exerting their antipsoriatic effects primarily by modulating DC activation and function.

  • Open Access

    Microbial functions in skin inflammation: a Mendelian randomization study

    byĀ Yujie Yang, Yiyuan Zhong, Peng Wu, MingXuan Li, Jingyi Cai, Qihong Chen, Xuwei Zheng, Haiming Chen, Teng Yu

    Inflammatory skin diseases (ISDs) represent a significant global health burden, yet the role of the human microbiome in their pathogenesis remains unclear.

  • Open Access

    Exploring therapeutic mechanism of Fuzhenghefuzhiyang Formula in psoriasis: inflammation and metabolism regulation

    byĀ Bin Tang, Chen Zhang, Yujie Yang, Haixin Zhong, Kexin Yang, Hao Deng, Jingjie Yu, Yonggen Chen, Xiangliang Deng, Chuanjian Lu, et al.

    Background: Psoriasis is a long-term, immune-mediated inflammatory disorder of the skin, affecting about 2-3% of the global population with rising prevalence rates. Clinical practice has demonstrated that Fuzhenghefuzhiyang formula (FZHFZY), a topical medication applied Chinese herbal formula developed by Prof. Lu Chuanjian, exhibits significant efficacy in alleviating psoriasis symptoms. Nevertheless, its mechanism of anti-psoriasis remains unclear. Purpose: The purpose of this study is to decode the molecular mechanisms by which FZHFZY produces its therapeutic effects on psoriasis using an integrated multi-omics approach. Methods: Employing both cell-based and animal studies, we systematically elucidate the pharmacodynamic substance basis and biological pathways underlying its anti-psoriasis effects by integrating network pharmacology to predict the active ingredient-target network, metabolomics to analyze endogenous metabolite changes, and transcriptome sequencing to dissect gene expression regulation. Results: FZHFZY effectively alleviated symptoms of skin thickening, erythema, and scaling in psoriatic model mice. Network pharmacology predicted that its therapeutic effect might be related to target pathways associated with inflammation, metabolism, proliferation, pyroptosis. RNA sequencing analysis of skin lesion tissues revealed that FZHFZY modulated the inflammation-related NOD-like receptor (NLR) and IL-17 signaling pathways. Further validation by RT-PCR showed that FZHFZY markedly downregulated the mRNA levels of IL-17 and NLRP3. Metabolomics analysis of the lesion tissues identified 169 differential metabolites, and FZHFZY was found to regulate the catabolism of carbohydrates, purines, and most amino acids. Cross-analysis of the two omics approaches indicated that purine metabolism and ether lipid metabolism were associated with key genes in the NLR signaling pathway identified by MCODE analysis. Conclusions: This study revealed that FZHFZY can effectively improve lesion conditions in a psoriasis-like mouse model, and its mechanism of action may be related to the association between purine metabolism, lipid metabolism, and key genes in the NLR signaling pathway.

  • Huanglian Wendan decoction alleviates metabolic syndrome by reprogramming macrophage polarization: Evidence from multi-omics integration

    byĀ Zuqing Su, Yanlin Li, Zihao Zhou, Lipeng Tang, Ying Zhu, Haiming Chen, Bing Feng, Guangjuan Zheng


  • Open Access

    Herbal Medicine for Colorectal Cancer Treatment: Molecular Mechanisms and Clinical Applications

    byĀ Zuqing Su, Yanlin Li, Zihao Zhou, Bing Feng, Haiming Chen, Guangjuan Zheng

    Colorectal cancer (CRC) is one of the most common malignant tumours and is the second leading cause of cancer‐related mortality worldwide. Despite the availability of preventative, diagnostic and treatment methods including endoscopic treatment, surgical intervention, radiotherapy, biologics, salvage therapy and immunotherapy, the mortality rate associated with CRC remains alarming. Consequently, there is a pressing need to search for medicines for the treatment of CRC. Phytomedicines have been shown to suppress the proliferation and metastasis of CRC through various mechanisms, including immune regulation, modulation of gut microbiota, targeting of stem cells, macrophage polarisation, glycolysis, ferroptosis induction, modulation of extracellular vesicles, activation of mitochondria‐induced apoptosis, inflammation reduction, oxidative stress management and intervention of autophagy. Furthermore, numerous studies have reported the anti‐cancer and anti‐metastatic effects of various phytomedicines, including curcumin, resveratrol, berberine, shikonin, dihydroartemisinin, fucoidan, luteolin, andrographolide, piperine, kaempferol, emodin, cannabidiol, tanshinone IIA and evodiamine. In this review, we sort out the effects and mechanisms of phytomedicines on CRC and outline the major phytomedicines commonly used in CRC treatment. We hope that these phytomedicines may serve as promising drugs or important lead compounds for the management of CRC.


  • Open Access

    Corrigendum: The causal relationship between serum metabolites and the risk of psoriasis: a Mendelian randomization and meta-analysis study

    byĀ Yujie Yang, Xuwei Zheng, Haiying Lv, Bin Tang, Yiyuan Zhong, Qianqian Luo, Yang Bi, Kexin Yang, Haixin Zhong, Haiming Chen, et al.

    In the published article, there was an error in Figure 4 as published. The duplicate Figure 4B was mistakenly uploaded to the position of Figure 4C. The corrected Figure 4 and its caption (A) displays the heterogeneity and pleiotropy analysis results of 24 metabolites that have been successfully validated. (B) displays the enrichment pathways of metabolites in KEGG and (C) displays the enrichment pathways of metabolites in SMPDE database appear below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.


  • Open Access

    The Role of Extracellular Vesicles in the Development and Treatment of Psoriasis: Narrative Review

    byĀ Bin Tang, Yang Bi, Xuwei Zheng, Yujie Yang, Xiaobing Huang, Kexin Yang, Haixin Zhong, Ling Han, Chuanjian Lu, Haiming Chen

    Psoriasis is a chronic inflammatory polygenic disease with significant impacts on skin and joints, leading to substantial treatment challenges and healthcare costs. The quest for novel therapeutic avenues has recently highlighted extracellular vesicles (EVs) due to their potential as biomarkers and therapeutic agents in autoimmune diseases, including psoriasis. EVs are nano-sized, lipid membrane-bound particles secreted by cells that have emerged as promising tools for targeted drug delivery, owing to their unique structure. This review delves into how EVs, either as mediators of cell communication or via their cargo (such as miRNA), directly participate in the pathology of psoriasis, influencing processes such as immune regulation, cell proliferation, and differentiation. Furthermore, this review explores the innovative application of EVs in psoriasis treatment, both as direct therapeutic agents and as vehicles for drug delivery, offering a novel approach to overcoming the current treatment limitations.


  • Open Access

    The causal relationship between serum metabolites and the risk of psoriasis: a Mendelian randomization and meta-analysis study

    byĀ Yujie Yang, Xuwei Zheng, Haiying Lv, Bin Tang, Yiyuan Zhong, Qianqian Luo, Yang Bi, Kexin Yang, Haixin Zhong, Haiming Chen, et al.

    Objective: To explore the influence of serum metabolites on the risk of psoriasis.Methods: In the initial stage, we applied Mendelian randomization to evaluate the association between 1,400 serum metabolites and the risk of psoriasis. Causal effects were primarily assessed through the Inverse-Variance Weighted method and Wald Ratio’s odds ratios, and 95% confidence intervals. False Discovery Rate was used for multiple comparison corrections. Sensitivity analyses were conducted using Cochran’s Q Test, MR-PRESSO. MR-Steiger Test was employed to check for reverse causality. In the validation stage, we sought other sources of psoriasis GWAS data to verify the initial results and used meta-analysis to combine the effect sizes to obtain robust causal relationships. In addition, we also conducted metabolic pathway enrichment analysis on known metabolites that have a causal relationship with the risk of psoriasis in both stages.Results: In the initial stage, we identified 112 metabolites causally associated with psoriasis, including 32 metabolite ratios and 80 metabolites (69 known and 11 unknown). In the validation stage, 24 metabolites (16 known, 1 unknown, and 7 metabolite ratios) were confirmed to have a causal relationship with psoriasis onset. Meta-analysis results showed that the overall effect of combined metabolites was consistent with the main analysis in direction and robust in the causal relationship with psoriasis onset. Of the 16 known metabolites, most were attributed to lipid metabolism, with 5 as risk factors and 8 as protective factors for psoriasis. Peptidic metabolite Gamma-glutamylvaline levels had a negative causal relationship with psoriasis, while exogenous metabolite Catechol sulfate levels and amino acid 3-methylglutaconate levels had a positive causal relationship with the disease onset. The metabolites associated with psoriasis risk in the two stages are mainly enriched in the following metabolic pathways: Glutathione metabolism, Alpha Linolenic Acid and Linoleic Acid Metabolism, Biosynthesis of unsaturated fatty acids, Arachidonic acid metabolism, Glycerophospholipid metabolism.Conclusion: Circulating metabolites may have a potential causal relationship with psoriasis risk, and targeting specific metabolites may benefit psoriasis diagnosis, disease assessment, and treatment.


  • Open Access

    Network pharmacology and gut microbiota insights: unraveling Shenling Baizhu powder’s role in psoriasis treatment

    byĀ Bin Tang, Xuwei Zheng, Qianqian Luo, Xiong Li, Yujie Yang, Yang Bi, Yonggen Chen, Ling Han, Haiming Chen, Chuanjian Lu

    Background: Psoriasis, a chronic skin condition characterized by systemic inflammation and altered gut microbiota, has been a target of Traditional Chinese Medicine (TCM) for centuries. Shenling Baizhu Powder (SLBZP), a TCM formulation, holds promise for treating inflammatory diseases, but its specific role in psoriasis and impact on gut microbiota is not fully understood.Objective: This study aims to elucidate the mechanism of SLBZP in treating psoriasis, integrating component analysis, network pharmacology, and experimental validation in mice models.Methods: We commenced with a detailed component analysis of SLBZP using liquid chromatograph and mass spectrometer (LC-MS). Network pharmacology analysis was used to predict the potential action targets and pathways of SLBZP in psoriasis. An in vivo experiment was conducted with psoriasis mice models, treated with SLBZP. Therapeutic effects were assessed via symptomatology, histopathology, and immunohistochemical analysis. Gut microbiota composition was analyzed using 16S rRNA gene sequencing.Results: A total of 42 main components and quality markers were identified, primarily from licorice and ginseng, including flavonoids, saponins and other markers. PPI topology analysis showed that TNF, IL-6, IL-1β, TP53 and JUN were the core DEPs. 168 signaling pathways including lipid and atherosclerosis, AGE-RAGE signaling pathway, IL-17 signaling pathway and Th17 cell differentiation were enriched by KEGG. SLBZP demonstrated significant therapeutic effects on psoriasis in mice, with alterations in skin pathology and biomarkers. Additionally, notable changes in gut microbiota composition were observed post-treatment, indicating a possible gut-skin axis involvement.Conclusion: This research has pinpointed lipid metabolism as a key pathway in the treatment of psoriasis with SLBZP. It explores how SLBZP’s modulation of gut microbiota and lipid metabolism can alleviate psoriasis, suggesting that balancing gut microbiota may reduce inflammation mediators and offer therapeutic benefits. This underscores lipid metabolism modulation as a potential new strategy in psoriasis treatment.


  • Open Access

    A bibliometrics study on the status quo and hot topics of pathogenesis of psoriasis based on Web of Science

    byĀ Yujie Yang, Xuwei Zheng, Haiying Lv, Bin Tang, Yang Bi, Qianqian Luo, Danni Yao, Haiming Chen, Chuanjian Lu

    Background: Psoriasis is an immune‐mediated chronic inflammatory skin disease. Great progress has been made in the pathogenesis of psoriasis in recent years, but there is no bibliometric study on the pathogenesis of psoriasis. The purpose of this study was to use bibliometrics method to analyze the research overview and hot spots of pathogenesis of psoriasis in recent 10 years, so as to further understand the development trend and frontier of this field.Methods: The core literatures on the pathogenesis of psoriasis were searched in the Web of Science database, and analyzed by VOSviewer, CiteSpace, and Bibliometrix in terms of the annual publication volume, country, institution, author, journal, keywords, and so on.Results: A total of 3570 literatures were included. China and the United States were the main research countries in this field, and Rockefeller University was the main research institution. Krueger JG, the author, had the highest number of publications and the greatest influence, and Boehncke (2015) was the most cited local literature. J INVEST DERMATOL takes the top spot in terms of the number of Dermatol articles and citation frequency. The main research hotspots in the pathogenesis of psoriasis are as follows: (1) The interaction between innate and adaptive immunity and the related inflammatory loop dominated by Th17 cells and IL‐23/IL‐17 axis are still the key mechanisms of psoriasis; (2) molecular genetic studies represented by Long Non‐Coding RNA (LncRNA); (3) integrated research of multi‐omics techniques represented by gut microbiota; and (4) Exploring the comorbidity mechanism of psoriasis represented by Metabolic Syndrome (MetS).Conclusion: This study is a summary of the current research status and hot trend of the pathogenesis of psoriasis, which will provide some reference for the scholars studying the pathogenesis of psoriasis.